But the most surprising development in obesity pharmacology is from Amgen: MariTide, a drug that targets the GIP receptor in the opposite direction of everyone else
Key findings Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Below is a Q&A with study senior author Dr
People may need to learn how to give an injection themselves or how to take the pill correctly
Psychological support through CBT or pain management programmes can address emotional eating, improve self-efficacy, and help patients develop healthier relationships with food and activity
As metabolism adapts, heat production can decrease slightly
Patients should maintain adequate fibre intake during remission, though this may need modification during flares